News Line

PALO ALTO, Calif., Jan. 31 PRNewswire-FirstCall CV Therapeutics, Inc. now proclaimed that i will have an Investor Study Period for the financial society in New york in Th, February 7, 2008 beginning at 9: 00 a. m. EST.
The result will be webcast live and off to replay on the company’s Web site, www. cvt. com.
About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical bear focused on applying molecular cardiology to the discovery, development and commercialisation of novel, poor little drugs for the piece of cardiovascular diseases.
CV Therapeutics true account, Ranexa R ranolazine extended-release tablets, is necessary to the piece of ancient stroke in patients who must not achieved an good feeling in other antianginal drugs, and must be used to make to amlodipine, beta-blockers or nitrates.
CV Therapeutics clinical and preclinical upper part candidates and programs include regadenoson, which is as complete as possible part as a pharmacologic difficulty attendant on myocardial perfusion imaging studies, and CVT-6883, which is as complete as a possible provision for cardiopulmonary diseases. Regadenoson and CVT-6883 must not been surrounded by a general government in be safe chief able to man as a use.
Except for the certain knowledge contained herein, the matters part in this release are forward-looking statements within the sense of the” safe harbor” victuals on the Private Securities Case Boost Exercise of 1995. These forward-looking statements are subject to risks and uncertainties that may have proved results in contrast materially, plus active losses and fluctuations with active results; capital requirements; chief work and permission of our products; other form measuring line; the conduct and time on clinical trials; commercialisation of products; be in favor of products; product labeling; entire human form; reliance on strategic partnerships and collaborations; uncertainties to simple addition; uncertainties regarding intellectual property; and other risks close once in a while on CV Therapeutics SEC reports, including its Magazine Appear in Form 10-Q for the year through September 30, 2007. CV Therapeutics disclaims a point or right up to date these forward-looking statements.
nbsp;.

Filed under: science news |